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Abstract: Candidemia is associated with high mortality rate especially in critically ill (ICU)
patients with septic shock and echinocandins such as anidulafungin are recommended
as first line treatment. Available pharmacokinetic studies of anidulafungin  in healthy
volunteers and in patients with renal or hepatic impairment showed that no dose
adjustment is needed even in patients receiving standard intermittent haemodialysis.
However, few data are available with continuous veno-venous haemofiltration (CVVH).
In this study the pharmacokinetic of anidulafungin was studied in two ICU patients with
candidemia and septic shock undergoing CVVH. Both patients had satisfactory
parameters of Cmax (9.04 mg/L and 5.68 mg/L, respectively), AUC (95.18 mg/L*h and
67.48 mg/L*h) and Cmin (2.61 mg/L and 1.43 mg/L). AUC/MIC ratio and Cmax/MIC
values were: 11887 and 8435; 1130,25 and 710, for patient 1 and 2 respectively. Our
data confirm that in patients with septic shock anidulafungin presents only mild
pharmacokinetic changes compared to data reported during CVVH alone.
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Introduction 1 
Bloodstream infections caused by Candida spp. are associated with a mortality of 30-2 
50%, especially in intensive care units (ICU), where the risk of invasive Candida 3 
infection is increased 
1
. Echinocandins such as anidulafungin are fungicidal against 4 
Candida spp. and are recommended as first line agents by the IDSA and ESCMID 5 
guidelines
1-3
. Anidulafungin has no known metabolism and undergoes spontaneous 6 
degradation at physiologic pH and temperature 
4
 and pharmacokinetic studies in healthy 7 
volunteers and in patients with renal or hepatic impairment demonstrated that no dose 8 
change is needed, also including patients undergoing standard intermittent 9 
haemodialysis
5-6
. 10 
In patients with septic shock the pharmacokinetic of antimicrobials may dramatically 11 
change owing to tissue perfusion, change of protein binding, drug clearance and fluid 12 
overload which may increase the volume of distribution of many drugs 
4
. Continuous 13 
veno-venous haemofiltration (CVVH) is frequently used in ICU patients with renal 14 
failure and the pharmacokinetic of antifungals may be altered, according to various 15 
parameters both patient-related and extracorporeal circuit-related, such as the ultrafiltrate 16 
and dialysate rates, dialysate concentrations and the type of membranes. 17 
There are very few data on pharmacokinetic of anidulafungin in ICU patients, either with 18 
septic shock or CVVH.  The aim of this study was to describe the pharmacokinetics of 19 
anidulafungin in two ICU patients with septic shock during CVVH. 20 
 21 
Material and methods 22 
Anidulafungin plasmatic concentrations were studied in two ICU patients with septic 23 
shock, receiving CVVH and treated with standard dosage (100 mg/die preceded by 24 
loading dose of 200 mg, 1 hour of infusion) for candidemia. The area under the curve 25 
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(AUC), Cmax and Cmin were determined by collecting blood samples during CVVH at 0, 1 
1, 5 and 8 hours after administration at steady state (after the day four from the beginning 2 
of maintenance dose). Plasma samples were obtained and centrifuged at 3000 rpm for 10 3 
minutes at 4°C; two samples were stored at -20°C until analysis. Anidulafungin was 4 
determined in plasma by ultra performance liquid chromatography-photo diode array 5 
detection (UPLC-PDA); a linear forced through zero calibration curve in the range of 15 6 
mg/L to 0.117 mg/L, was used. Mean accuracy expressed as relative accuracy % was 7 
94.4%. Precision, expressed as relative standard deviation %, was 6.39. Pharmacokinetic 8 
data were obtained using Kinetica Software (Thermo Scientific, Waltham, 9 
Massachusetts, USA). A non-compartmental steady state model was used.  10 
The patients main clinical, microbiological and laboratory data are illustrated in Table 1. 11 
Notably, patient 2 was receiving tacrolimus and cyclosporine because of heart transplant. 12 
 13 
Results 14 
Patients’ clinical and microbiological characteristics are illustrated in Table 1. Mean 15 
Cmax, Cmin, AUC, half life, clearance and volume of distribution were: 9.04 Vs. 5.68 16 
mg/L; 2.61 Vs. 1.43 mg/L; 95.18 Vs. 67.48 mg/L*h; 31.99 Vs. 15.34 h; 2.6 Vs. 1.48 L/h;  17 
48.48 Vs. 32.81 L for patient 1 and 2,respectively. 18 
Discussion 19 
The effect of septic shock on serum drug concentrations may be altered owing to 20 
increased cardiac output, infusion of liquids, increased or decreased clearances with 21 
secondary alterations of the volume of distribution; such changes may result in 22 
insufficient dosages of antimicrobials, either for concentration- and time-dependent 23 
molecules. Echinocandins are fungicidal against Candida spp. and are concentration-24 
dependent with best activity described by Cmax/MIC and AUC/MIC 
4, 6
: anidulafungin 25 
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has the highest volume of distribution and, at least in theory, plasma concentration in 1 
patients with septic shock may vary even if  lipophylic molecules, such as anidulafungin, 2 
better tolerate changes in body fluid volume 
7, 8 
. In ICU patients CVVH is commonly 3 
used in septic patients with renal failure and it may further contribute to pharmacokinetic 4 
alterations, depending on several variables, such as the ultrafiltrate and dialysate rates 5 
and the type of membrane used.  6 
Available data in non-ICU population pharmacokinetic analysis for anidulafungin show 7 
that pharmacokinetic parameters associated with success include AUC at steady state >35 8 
mg/L*h and minimum plasma concentration at steady state (Cmin) >1 mg/L
6
. The 9 
strongest relationship with antifungal effect in animal models, considering the 10 
pharmacokinetic/ pharmacodynamic parameters, was observed with AUC/MIC ratio of 11 
250 and Cmax/MIC > 4 
5, 9
. 12 
Our patients did achieve AUC/MIC >250 and Cmax/MIC > 4, perhaps due also to the very 13 
low MIC of C. albicans tested. These results underscore that even in patients with septic 14 
shock receving CVVH anidulafungin has a very good pharmacokinetic profile. 15 
According to the available literature, both patients (1 and 2, respectively) had satisfactory 16 
parameters of Cmax, AUC and Cmin. AUC/MIC ratio and Cmax/MIC values considering the 17 
MIC for Candida albicans (0.008 mg/L) were 11887 and 8435; 1130,25 and 710, 18 
respectively, for patient 1 and 2. Notably, pharmacokinetic data for patient 2 confirm that 19 
there are no significant interactions with tacrolimus or cyclosporine. 20 
Of course we proceeded to simulate AUC/MIC ratio for different Candida MICs: the 21 
ratios were 5948 and 4217 for patient 1 and 2, respectively, with MIC of 0.016 mg/L; 22 
761 and 539 for MIC of 0.125 mg/L. The simulated values of Cmax/MIC considering MIC 23 
values of 0.016 mg/L were 565.13 and 355, changing to 72.34 and 45.44 for patient 1 and 24 
2, respectively with MIC of 0.125 mg/L. Despite early and appropriate empiric treatment 25 
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with anidulafungin before microbiological confirmation of candidemia and plenty 1 
satisfaction of pharmacokinetic parameters, both patients were dead at 21 days after 2 
diagnosis, with negative blood cultures at 48 hours after diagnosis. 3 
To our knowledge there are few data on pharmacokinetic of anidulafungin in ICU 4 
patients and no data are available in patients with septic shock undergoing CVVH. A case 5 
report in the ICU setting by Burkhardt reported that anidulafungin does not necessitate 6 
dose adjustment with septic shock undergoing extended daily dialysis 
10
. However, 7 
pharmacokinetic parameters were only studied at the first day of treatment, when the 8 
loading dose was administered: Cmax, Cmin and AUC values were 5.32 mg/L, 1.60 mg/L 9 
and 55.2 mg *h/L, respectively. Leitner et al. described 10 patients receiving CVVH, 10 
three of which with septic shock, with a CVVH ultrafiltration rate of 1500 ml/h, an 11 
extended 3-h anidulafungin loading dose infusion and 1.5-h infusion mainteinance dose 12 
11
. Cmax values were evaluated at day 1, 2 and 3 whilst AUC was determined only during 13 
the first day. This study reported a mean Cmax of 5.9+ 2 mg/L at day 3 and a mean arterial 14 
AUC of 109.9+ 49.82 mg*h/L at day 1. According to these data, the Authors concluded 15 
that dose changes are not needed during CVVH. 16 
In conclusion, anidulafungin treatment of ICU patients with septic shock and CVVH did 17 
confirm that no dose changes are needed compared to patients treated with CVVH alone.  18 
 19 
 20 
 21 
 22 
 23 
 24 
 25 
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Table 1. Patients’ clinical and microbiological characteristics. 1 
 Patient 1 Patient 2 
Sex Female Male 
Age (year) 69 56 
BMI 28 31 
Comorbidities Hypertension, diabetes, 
 ischemic cardiopathy. Berger’s nephritis. 
Peritoneal dialysis.  
Prosthetic aortic valve 
Diabetes. Heart transplant complicated by 
surgical site infection and AKI.  
Immunesuppression with tacrolimus and 
cyclosporine 
 
 
Days of ICU at diagnosis 20 24 
Creatinine (mg/dl) 2.3  2.2  
Albumin (mg/dl) 2.4 2.5 
AKI/CRF CRF AKI 
Therapy with Amine yes/no Yes Yes 
Blood cultures C. albicans C. albicans 
CVVH (ml/h) 2000 1800 
MIC for 
Anidulafungin 
(mg/L) 
 
<0.008 <0.008 
Candida score12 4 4 
 2 
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